Target intelligence / Profile preview

Clostridium septicum alpha toxin (AT) (AT)

Target
AT
Molecular classification
Bacterial exotoxin, Pore-forming toxin, Aerolysin-like toxin
01

Overview

Clostridium septicum alpha toxin is the principal virulence factor produced by the Gram-positive, anaerobic bacterium Clostridium septicum (UniProt P17023). It is secreted as an inactive 46 kDa protoxin that requires proteolytic activation, typically by host cell surface proteases like furin, which removes a C-terminal peptide (Knapp et al., J. Biol. Chem., 1997). Once activated, the toxin binds to glycosylphosphatidylinositol (GPI)-anchored proteins on the host cell membrane, where it oligomerizes to form a heptameric prepore (Gordon et al., J. Biol. Chem., 1999). This prepore then inserts into the membrane to create a stable aqueous pore, leading to the rapid efflux of potassium ions, influx of calcium, and eventual cell lysis or apoptosis (Kennedy et al., Mol. Microbiol., 2005). In clinical settings, this toxin is the primary driver of gas gangrene (clostridial myonecrosis) and is frequently associated with underlying malignancies, particularly of the gastrointestinal tract (StatPearls, 2023). Therapeutic strategies focus on the use of antitoxins to neutralize the toxin's activity and antibiotics to eliminate the source bacteria, as the toxin's rapid action often leads to high mortality rates if not addressed immediately (Stevens et al., Clin. Infect. Dis., 2014).

Other names
Alpha-toxinC. septicum alpha-toxinLethal toxinPore-forming toxin alpha
02

Mechanism of action

Neutralization of the toxin by specific antibodies to prevent binding to host cell receptors and subsequent pore formation (Mol. Microbiol., 2005).

03

Biological functions

Pore formationCytolysisHemolysisCell deathInduction of apoptosis
04

Disease associations

Gas gangreneClostridial myonecrosisNeutropenic enterocolitisSepsisBacteremia
05

Safety considerations

Rapid disease progression (StatPearls, 2023)High mortality rate (Clin. Infect. Dis., 2014)Systemic toxicity and multi-organ failure (Mol. Microbiol., 2005)Extensive tissue necrosis requiring surgical intervention (StatPearls, 2023)
06

Interacting drugs

Clostridium septicum antitoxin

1 more in the full profile.

07

Biomarkers

Clostridium septicum alpha toxin presence in serum or tissue (StatPearls, 2023)Clostridium septicum DNA detection via PCR (StatPearls, 2023)Elevated serum lactate levels as a prognostic indicator (Clin. Infect. Dis., 2014)

Beyond the preview

Go deeper on Clostridium septicum alpha toxin (AT) (AT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clostridium septicum alpha toxin (AT) (AT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call